Moderna finds promise in the private COVID vaccination market and the debut of RSV as sales plummet

Moderna Eyes Private COVID Market and RSV Launch as Sales Drop

Source – Fiercepharma

As Moderna continues its operations beyond the pandemic, the biotech firm has increased its revenue projection for the COVID-19 vaccine, expecting a strong performance in the private market. The company has also set its sights on potential new launches for the future.

Despite experiencing a significant decline in sales during the second quarter, Moderna has raised its sales guidance for Spikevax (its COVID-19 vaccine) to a range of $6 billion to $8 billion. This adjustment comes after generating $344 million in the second quarter of 2023, which is a sharp 93% drop compared to the $4.75 billion it earned in the same period the previous year. Additionally, the company reported a quarterly loss of $1.4 billion.

Moderna believes that new commercial contracts will provide better visibility into the expected sales for the rest of the year, although the total market size for COVID vaccines remains uncertain for the upcoming fall season. The company estimates around 100 million COVID vaccine doses to be administered in the US during the fall, lower than the average of 150 million doses typically given during a regular flu season.

Related: Moderna Submits Global Regulatory Applications For Its RSV Vaccine, MRNA-1345

Labeling this year as “transitional,” Moderna is shifting some focus to other projects, including its respiratory syncytial virus (RSV) vaccine. The company has already begun the FDA submission process for the RSV vaccine, with a planned launch in 2024, trailing behind competitors GSK and Pfizer, both of whom secured approvals this year. Despite the delayed launch, Moderna’s chief commercial officer, Arpa Garay, expressed confidence in the product’s “best-in-class profile” and remains hopeful for its success, anticipating a gradual uptake initially, but with potential for acceleration following a CDC recommendation.

Additionally, Moderna’s adjuvant melanoma vaccine is making progress, enrolling patients for a Phase III trial, and has garnered positive attention from analysts who see its potential to revolutionize melanoma treatment.

Related: Moderna To Research And Manufacture MRNA Meds In China Under $1B Agreement

In summary, Moderna is optimistic about its COVID-19 vaccine’s performance in the private market and is looking forward to future launches, including the RSV vaccine and the adjuvant melanoma vaccine. The company acknowledges the challenges but remains confident in the value of its products and their potential impact on public health.

Share This News